DMPS (2,3-dimercapto-1-propanesulfonic acid sodium), also known as Dimovol, is a synthetic amino acid chelating agent of toxic heavy metals, which forms a water soluble complex with toxic heavy metals and is believed by many to lead to their removal through the kidneys, liver, gastrointestinal tract. DMPS has been use in West Germany where it has been studied and is available as a commercial drug for the treatment of heavy metal toxicity. Studies in West Germany report safety in animals and humans in the doses given. DMPS does not appear to be toxic. Because DMPS has not been studied in the United States of America , it is considered "experimental" by the FDA.

DMPS chelation can be administered either by intravenous (I.V.), intramuscularly (I.M.), or by subcutaneous injection (S.Q.). The preferred administration is via an I.V. "push," pushing about 10 CC of solution. The I.V. push uses a syringe in which the nurse inserts the catheter into the patient's vein, the catheter is connected with clear tubing to a large syringe containing the DMPS solution, and the patient usually takes charge to slowly push the solution into their vein over about a 20 - 30 minute period of time. In contrast, EDTA chelation is very "hot" to the veins, is mixed usually into a 500 CC solution, and must be administered via a very slow I.V. "drip" which will take about 3 - 4 hours to administer.

Possible side effects include: temporary lowering of blood pressure or tackycardia, vertigo, general weakness or paleness 5 - 10 minutes after injection, and infiltration into the soft tissue which may create local itching that can last 30 minutes. Symptoms have been shown to generally be reversible after discontinuation of the drug. Aggravation of the metal related symptoms may result from the mobilization of heavy metals over the following several days after receiving DMPS treatment.